SAS Output

24-MAR-2017 18:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1007 Breast,Adj,N1,Endocrine+/-Chemo 15-JAN-11 440 215
  S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 466 240
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 239 109
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 249 106
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 257 121
  A011203 Breast, Adv, Tam vs Endoxifen 27-JAN-15 240 91
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 215 105
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 399 182
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 263 92
  E2112 Brst,Adv,Exemestane+/-Entinostat 02-JAN-14 305 171
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 438 217
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 49 60
  S1417CD Colorectal, Cost Cohort Study 13-MAY-16 239 69
  A011104 Preoperative Breast MRI 21-FEB-14 173 59
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 157 72
  A071102 GBM, adj TMZ +/- Veliparib 19-SEP-14 348 155
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 231 100
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 215 111
  EAY131 MATCH 12-AUG-15 432 221
 
GI S1313 Panc,Met,mFolfirinox+/-PEGPH20 06-JAN-14 75 26
  S1505 Panc,Resect, Perioperative Chemo 12-OCT-15 297 119
  S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 01-SEP-16 225 103
  E7208 CRC,Adv, Irino/Cet+/-Ramucirumab 20-FEB-14 206 85
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 167 63
  N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX 13-JAN-12 0 160
  R0848 Panc, Adj, Erlotinib v ChemoRT 01-MAR-14 0 147
 
GU S1011 Blad, Standard vs Extended LND 01-AUG-11 11 20
  S1216 Pros Adv, ADT +/- TAK-700 or Bic 01-MAR-13 143 150
  S1314 Blad, COXEN Neoadj. Chemo + Cyst 11-JUL-14 232 113
  S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 189 81
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 71 34
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 21 15
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 5 3
  E2810 Renal, Pazopanib vs Placebo 17-APR-12 180 88
  EA8141 UTUC, HG, Chemo then Surg 27-JAN-15 156 74
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 162
 
LEUK S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP 01-APR-14 5 6
  S1318 ALL, Age 65+, Ph±, Blinatumomab 12-JAN-15 178 70
  S0919 Rel AML: Pravastatin+Ida+Ara-C 15-AUG-09 86 28
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 153 78
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 151 80
  NHLBIMDS LEUK, National MDS Study 05-APR-16 8 5
 
LUNG S1400 SCCA,Adv, Biomarker Master 15-JUN-14 433 214
  S1400G HRRD: Talazoparib (BMN 673) 07-FEB-17 406 192
  S1400I Non-Match: Nivo + Ipi vs Nivo 18-DEC-15 436 218
  S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab 25-MAR-15 221 88
  S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 18-JUL-16 161 76
  8811 NSCLC, Stage III,ChemoRT+ABT-888 02-JAN-13 77 27
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 242
  A151216 ALCHEMIST0 - screening 06-FEB-14 455 244
  C140503 NSCL, Lobect v Sublobar resect 09-JUL-07 100 57
  C30610 SCLC, Thoracic RT 21-MAR-08 237 111
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 461 245
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 426 217
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 282 117
  R1306 NSCLC,Adv,ALK/EGFR,TargetAgents 04-NOV-13 157 67
 
LYMPH 9177 NHL, dose-adj. EPOCH+/-Rituximab 13-APR-12 59 25
  C51101 CNS, myelo/non-myelo chemo, PhII 22-JUN-12 61 28
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 238 98
  S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 15-OCT-15 403 161
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 37 18
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 319 129
  EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim 01-MAR-16 259 98
 
MMYEL E1A11 MM, frontline, BLD vs CLD 22-NOV-13 300 125
  E3A06 AMM, Lenalidomide vs Observation 08-NOV-10 271 122
 
OTHER A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo 02-SEP-14 35 18
  A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II 26-JAN-15 133 47
  A091305 HN, Adv, Thyroid PPAR agonist + Chemo 01-SEP-14 52 17
  A091401 Sarc, 18-JUN-15 195 75
  A091404 HN, AR+, Enzalutamide 25-SEP-15 2 2
  AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2 02-JUL-15 74 42
  E3311 Oroph,Srg + Low or Std IMRT 01-MAR-14 171 64
  EAQ152 Communication & education in tumor profiling 26-SEP-16 153 64
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 89
  NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo 04-FEB-16 314 139
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 73 36
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 199 74
  NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo 27-OCT-14 284 103
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 228 92
  R0920 HN, Adv, Postop IMRT ± Cetuximab 24-DEC-13 399 169
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 275 116
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 294 99
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 27 6
  A211201 Breast Density, MA.32 companion 22-AUG-12 58 14
 
SURV S1316 Compar. Effectiv. Trial for MBO 09-MAR-15 10 14
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 31
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 218 85
  A221102 Brst,AI Arthralgia,Testosterone 07-SEP-12 0 66